BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27115836)

  • 1. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review.
    Serrano OK; Love C; Goldman I; Huang K; Ng N; Abraham T; Da Silva R; Friedmann P; Libutti SK; Kennedy TJ
    J Surg Oncol; 2016 May; 113(6):640-6. PubMed ID: 27115836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
    Chen J; Cheong JH; Yun MJ; Kim J; Lim JS; Hyung WJ; Noh SH
    Cancer; 2005 Jun; 103(11):2383-90. PubMed ID: 15856477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer.
    Oh HH; Lee SE; Choi IS; Choi WJ; Yoon DS; Min HS; Ra YM; Moon JI; Kang YH
    J Surg Oncol; 2011 Oct; 104(5):530-3. PubMed ID: 21618250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer.
    Coupe NA; Karikios D; Chong S; Yap J; Ng W; Merrett N; Lin M
    Ann Nucl Med; 2014 Feb; 28(2):128-35. PubMed ID: 24297388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between 18F-FDG PET/MRI and MDCT for the assessment of preoperative staging and resectability of gastric cancer.
    Lee DH; Kim SH; Joo I; Hur BY; Han JK
    Eur J Radiol; 2016 Jun; 85(6):1085-91. PubMed ID: 27161056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
    Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
    Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
    Suzuki H; Hasegawa Y; Terada A; Ogawa T; Hyodo I; Suzuki M; Nakashima T; Tamaki T; Nishio M
    Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1191-5. PubMed ID: 19015450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
    Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
    J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer.
    Kaneko Y; Murray WK; Link E; Hicks RJ; Duong C
    J Nucl Med; 2015 Apr; 56(4):523-9. PubMed ID: 25745094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of baseline
    Foley KG; Coomer W; Coles B; Bradley KM
    Br J Radiol; 2022 Oct; 95(1139):20220437. PubMed ID: 36129138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hepatoid adenocarcinoma of the stomach evaluated with (18)F-FDG PET/CT: intense (18)F-FDG uptake contrary to the previous report.
    Seo HJ; Chung JK; Go H; Cheon GJ; Lee DS
    Clin Nucl Med; 2014 May; 39(5):442-5. PubMed ID: 24152637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.